CHA Vaccine Research Institute (KOSDAQ:261780)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,575.00
-135.00 (-4.98%)
At close: Mar 9, 2026
-15.02%
Market Cap 69.18B
Revenue (ttm) 158.62M
Net Income (ttm) -14.25B
Shares Out 26.87M
EPS (ttm) -531.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 82,352
Average Volume 93,495
Open 2,700.00
Previous Close 2,710.00
Day's Range 2,560.00 - 2,700.00
52-Week Range 2,360.00 - 3,660.00
Beta 0.58
RSI 44.77
Earnings Date n/a

About KOSDAQ:261780

Cha Vaccine Research Institute Co., Ltd., a research-oriented biotechnology company, researches and develops a range of vaccine products for infectious and chronic diseases. Its product pipeline includes HBV vaccine that is in Phase IIb planning for the prevention of hepatitis B; Adjuvanted HBV vaccine that is in Phase I/IIa for the treatment of chronic hepatitis B; and VZV Vaccine, which is in pre-clinical planning stage for the prevention of Herpes Zoster. The company also develops influenza vaccine, recombinant MBL, TB vaccine, and cancer va... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 261780
Full Company Profile

Financial Performance

In 2024, KOSDAQ:261780's revenue was 370.66 million, an increase of 26.02% compared to the previous year's 294.12 million. Losses were -10.14 billion, 479.5% more than in 2023.

Financial Statements

News

There is no news available yet.